Division of Cardiothoracic surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Division of Cardiovascular medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Catheter Cardiovasc Interv. 2020 Dec;96(7):E723-E734. doi: 10.1002/ccd.28862. Epub 2020 Apr 3.
To evaluate the impact of increased pulmonary artery systolic pressure (PASP) on outcomes after transcatheter aortic valve replacement (TAVR).
A total of 242 patients who underwent TAVR were retrospectively reviewed. Transthoracic echocardiography estimated PASP. The cohorts were divided into three groups according to the numerical change of PASP; Increased (post-TAVR PASP at 1 month minus pre-TAVR PASP, ≥ + 5 mmHg; n = 52), No change (-5 to +5 mmHg; n = 86) and Decreased (≤ -5 mmHg; n = 104). Patient demographics and clinical outcomes until 1 year were evaluated. Logistic regression model was used for multivariate risk analysis.
At 1 year, the Increased group showed higher mortality (21 ± 6%) than the No change group (5 ± 2%) (hazard ratio [HR]: 4.8, 95% confidence interval [CI]: 1.7-13.5; p < .01) and the Decreased group (8 ± 3%) (HR: 2.8, 95% CI: 1.1-6.7; p = .02). Rehospitalization rate for valve-related or heart failure was also higher in the Increased group (21 ± 6%) than the No change group (10 ± 3%) (HR: 2.4, 95% CI: 1.1-6.0; p = .04). Predictors of PASP deterioration were hypertension (odds ratio [OR]: 3.9, 95% CI: 1.1-13.8; p = .04) and left ventricular end-diastolic diameter >50 mm (OR: 2.2, 95% CI: 1.1-4.6; p = .04), and the increased PASP remained an independent predictor of 1-year all-cause mortality (HR; 2.7, 95% CI: 1.0-6.8; p = .04).
Regardless of the baseline PASP, patients with increased PASP at 1 month after successful TAVR were at higher risk of mortality and rehospitalization within 1 year. Strict medical management should be considered for patients who showed dilated left ventricle preoperatively.
评估肺动脉收缩压(PASP)升高对经导管主动脉瓣置换术(TAVR)后结局的影响。
回顾性分析 242 例接受 TAVR 的患者。经胸超声心动图估计 PASP。根据 PASP 的数值变化将患者分为三组;升高组(TAVR 后 1 个月的 PASP 减去 TAVR 前的 PASP,≥+5mmHg;n=52)、不变组(-5 至+5mmHg;n=86)和降低组(≤-5mmHg;n=104)。评估患者的人口统计学特征和 1 年的临床结局。采用多变量风险分析模型进行逻辑回归分析。
1 年后,升高组的死亡率(21±6%)高于不变组(5±2%)(危险比[HR]:4.8,95%置信区间[CI]:1.7-13.5;p<.01)和降低组(8±3%)(HR:2.8,95%CI:1.1-6.7;p=0.02)。升高组因瓣膜相关或心力衰竭再次住院的比例(21±6%)也高于不变组(10±3%)(HR:2.4,95%CI:1.1-6.0;p=0.04)。PASP 恶化的预测因素是高血压(比值比[OR]:3.9,95%CI:1.1-13.8;p=0.04)和左心室舒张末期直径>50mm(OR:2.2,95%CI:1.1-4.6;p=0.04),而升高的 PASP 仍然是 1 年全因死亡率的独立预测因素(HR;2.7,95%CI:1.0-6.8;p=0.04)。
无论基线 PASP 如何,TAVR 后 1 个月 PASP 升高的患者在 1 年内的死亡率和再住院率更高。对于术前左心室扩张的患者,应考虑进行严格的药物治疗。